# Clinical Study of EZH2 Inhibitor Combined With PARP Inhibitor in the Treatment of Patients With Advanced or Recurrent Epithelial Ovarian Cancer.

> **NCT07339553** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Peking University Third Hospital** · enrollment: 30 (estimated)

## Conditions studied

- Ovariancancer
- Platinum-sensitive Recurrent

## Interventions

- **DRUG:** Treatment

## Key facts

- **NCT ID:** NCT07339553
- **Lead sponsor:** Peking University Third Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-01-04
- **Primary completion:** 2029-01-30
- **Final completion:** 2029-02-26
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-01-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07339553

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07339553, "Clinical Study of EZH2 Inhibitor Combined With PARP Inhibitor in the Treatment of Patients With Advanced or Recurrent Epithelial Ovarian Cancer.". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT07339553. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*